insitro and Bristol Myers Squibb sign ALS drug-discovery collaboration

insitro/ML-driven target discovery

insitro and Bristol Myers Squibb entered a five-year collaboration to find new treatments for amyotrophic lateral sclerosis and frontotemporal dementia using insitro's machine-learning platform and patient-derived cell models. insitro received $50 million upfront and is eligible for over $2 billion in milestones plus royalties; BMS runs clinical development.

• $50 million upfront; over $2 billion in discovery, development, regulatory, and commercial milestones; royalties on net sales.
• insitro's Human platform uses induced pluripotent stem cells (iPSCs) to model disease; BMS handles clinical development and commercialization.
• Neither ALS nor FTD currently have disease-modifying treatments; insitro has options to select targets for further development.